Substantial changes included: ● Revised treatment failure parameters and efficacy variables where referenced throughout the document to reflect updated scientific approach and statistical analyses. ● Exclusion Criteria: changed BCVA worse than 20/400 to 20/200 and logMar from "> 1.34" to "> 1.0." ● Exclusion Criteria: added "All subjects with intermediate uveitis must have had a prior brain MRI at time of or after diagnosis of intermediate uveitis" to ensure that patients with intermediate uveitis do not have demyelinating disease such as multiple sclerosis, an appropriate diagnostic work up should include a brain MRI. ● Concomitant Therapy: added text regarding the use of topical or systemic corticosteroids.

Substantial changes included: ● Revised the description of primary endpoint with regard to fundus visualization and to make editorial changes. ● Exclusion criteria: Added exclusion of subjects with severe vitreous haze that precludes visualization of the fundus to ensure the appropriate subject population is studied. ● Best Corrected Visual Acuity Testing: Removed the requirement that the individual performing refraction and BCVA testing not be the Principal Investigator nor the same person entering data on the eCRFs; there are no restrictions on who the BCVA examiners are for this study; however, they must be proficient in ETDRS refraction and ETDRS visual acuity measurement, and they must be certified by standardization vendor in both those study tasks. ● Study Procedures/Oral Prednisone Taper: Added text regarding oral prednisone taper to clarify that no deviations from the oral prednisone taper are allowed.

Substantial changes included: ● Inclusion Criterion: Added "Subject with prior adequate response to corticosteroids (equivalent of prednisone up to 1 mg/kg/day)" to clarify the intent of Exclusion Criterion No. 2 which defines the appropriate subject population for this trial. ● Exclusion Criterion: Added Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, HZV (herpes zoster virus) as examples of potential infectious causes of uveitis. ● Exclusion Criterion: Revised to read "Subject has previous exposure to anti-TNF therapy and any biologic [including anti vascular endothelial growth factor (VEGF) therapy with a potential therapeutic impact on non-infectious uveitis" to provide clarification that prior anti VEGF therapy is also considered exclusionary for this clinical trial. ● Prohibited Therapy: Added "anti-VEGF therapy" and "periocular, intraocular or intravitreal injections" to clarify that anti-VEGF therapy, periocular, intraocular or intravitreal injections are not allowed during the study. ● Study Activities Table: Added Magnetic Resonance Imaging (MRI) to ensure the appropriate subject population is studied. ● Study Procedures: Indicated the correct order the eye exams are to be performed to ensure that the tests are done in the correct order to maximize the result of these procedures. ● Secondary Variables: Addition of change in Anterior Chamber (AC) cells to indicate that information collected on AC cell count/grade would not only be a component of the primary endpoint but also be evaluated as a secondary efficacy variable. ● Added Human Immunodeficiency Virus (HIV) testing Screening visit for Japanese subjects to satisfy local requirements in Japan.

Substantial changes included: ● Inclusion Criteria and Study Procedures: - Added option to use QuantiFERON®-TB Gold for tuberculosis screening. - Added instruction that subjects with positive PPD and or QuantiFERON® TB Gold, history of active or latent tuberculosis [TB] or chest x-ray indicative of latent TB will be required to initiate and take at least 2 weeks of an ongoing course of prophylaxis prior to starting study therapy. ● Exclusion Criterion: - Changed to exclude subjects with 1 immunosuppressive therapy with dose increase within previous 28 days or who are on a dose outside of the allowed range listed and clarified that the dose of 1 allowable concomitant immunosuppressive therapy must be in the allowable range at Baseline. - Added text to exclude subjects with macular edema due to diabetic retinopathy. - Added Ozurdex® (dexamethasone implant) and intravitreal methotrexate (MTX) as prohibited therapy. - Added exclusion criterion that allows the prior use of intravitreal anti-VEGF therapy provided a 3 month washout period from Baseline is observed. - Added text to exclude use of marijuana in the previous 12 months. - Exclude hepatitis B surface antigen (HBsAg) positive subjects or subjects who are positive for either hepatitis surface antibodies (HBsAb) and/or core antibodies (HBcAb, Total), and HBV DNA PCR result that meets or exceeds detection sensitivity. ● Added requirement if at Week 52, a subject has a positive TB test subjects will undergo a standard Chest X-ray. ● Discontinuation of Individual Subjects: added dysplasia of the gastrointestinal tract, diagnosis of lupus like syndrome, multiple sclerosis or demyelinating disease and non-compliance with TB therapy.

Substantial changes included: ● Added text to exclude use of systemic carbonic anhydrase inhibitor within 1 week prior to Screening visit and as prohibited therapy. ● Added instruction to evaluate subjects for treatment failure criteria at Unscheduled visits (as applicable) and complete Unscheduled visit activities per the investigator's clinical judgment. ● Added instruction to use the same fundus camera throughout the study per subject.

Substantial changes included: ● Limited the maximum corticosteroid dose at study start to ≤ 60 mg/day. ● Removed allowance for subjects with positive TB tests except where a subject received a BCG vaccination or has a history of an ulcerative reaction to a PPD skin test. If the PPD test is positive, the QuantiFERON®-TB Gold test (or equivalent) must be performed. If the QuantiFERON®-TB Gold test (or equivalent) is negative, the subject is eligible. ● Changed BCVA score to < 34 letters. ● Added exclusion for those subjects who have had Retisert® (glucocorticosteroid implant) removed less than 90 days before Baseline or had complications related to the removal of the device. ● Changed exclusion of subjects with macular edema due to diabetic retinopathy to subjects with clinically significant macular edema due to diabetic retinopathy. ● Modified that both Fluorescent Treponemal Antibody (FTA) and Rapid Plasma Reagin (RPR) must be tested. If RPR or FTA is positive, the subject is excluded. ● Added criterion to exclude subjects with macular edema as the only sign of uveitis. ● Added criterion to exclude subjects with a history of scleritis. ● Added criterion to exclude subjects who require TB-prophylaxis. ● Added "Retisert® (glucocorticosteroid implant)" to list of prohibited medications. ● Changed secondary efficacy variable analysis to be percent change in central retinal thickness. ● Added hypotony to the list of uveitis related events.

Substantial changes included: ● Revised language to include subjects with either negative PPD (< 5 mm of induration) or negative QuantiFERON®-TB Gold test (or Interferon-Gamma Release Assay [IGRA] equivalent) as eligible. ● Added that subjects with "previous" TB are also not eligible for this study. ● Reduced the number of letters a subject must read for BCVA to 20 letters. ● Added tacrolimus as an acceptable concomitant immunosuppressant ● Allow prior use of cyclophosphamide provided a 30 day washout prior to Baseline is observed. Added chlorambucil and cyclophosphamide to prohibited concomitant medication list. ● Reduced the washout period for intraocular or periocular corticosteroids to 30 days. ● Reduced intravitreal anti-VEGF therapy washout periods for Lucentis® (ranibizumab) or Avastin® (bevacizumab) to 45 days of the Baseline visit or for anti-VEGF Trap (Aflibercept) for 60 days of the Baseline visit. ● Allow refractive laser surgery, retinal laser photocoagulation or Nd:YAG capsulotomy (neodymium-doped yttrium aluminium garnet (YAG)) laser ≥ 30 days prior to Baseline visit. ● Removed Rapid Plasma Reagin testing. Syphillis testing will consist of Fluorescent Treponemal Antibody (FTA) testing only. ● Added that each vaccine administered to the subject should be listed as a concomitant medication on the Other Medications eCRF. Live vaccines may not be given concurrently while on study drug or for 70 days after the last dose of adalimumab. ● Changed reporting of uveitis-related events such that standard adverse reporting procedures apply for all adverse events regardless of the relationship to uveitis.

Substantial changes included: ● Reordered ranking of secondary variables: The Anterior Chamber (AC) Cell grade and Vitreous Haze grade ranking were changed based on observed reasons for treatment failure in the blinded data. ● Removed interim analyses and reduced the total number of treatment failures to complete the study. ● Added language and new requirements regarding malignancy in patients who are 30 years old or younger. ● Adverse Event Reporting changed to require non-serious events of malignancy in subjects 30 or younger to be reported to Abbvie within 24 hours of site awareness.

Substantial changes included: ● Added Rituxan® (rituximab) as prohibited therapy. ● Subjects with optic neuritis are exclusionary. ● Added Stelara® (ustekinumab), Benlysta® (belimumab), and corticosteroids with the exceptions of protocol specified prednisone taper and the protocol specified corticosteroid eye drop taper as prohibited medications.

Substantial changes included: ● Increased overall sample size to 266 subjects (including 32 Japanese subjects) and increased the number of required treatment failures to 138 events and 19 events in subjects enrolled in Japan in order to maintain a power of 90%. ● Changed the definition of secondary endpoints to be able to include those subjects in the analysis that have a treatment failure at Week 6.